Vanda Pharmaceuticals Inc (VNDA):企業の財務・戦略的SWOT分析

◆英語タイトル:Vanda Pharmaceuticals Inc (VNDA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140528FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Vanda Pharmaceuticals Inc (VNDA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vanda Pharmaceuticals Inc (Vanda) is a specialty pharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. Its pipeline portfolio includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis; VQW-765, an alpha-7 nicotinic acetylcholine receptor for CNS disorders; and VTR-297 for oncology indications. Vanda is headquartered in Washington DC, the US.

Vanda Pharmaceuticals Inc Key Recent Developments

Oct 28,2020: Vanda Pharmaceuticals reports third quarter 2020 financial results
Aug 05,2020: Vanda Pharmaceuticals reports second quarter 2020 financial results
May 20,2020: Vanda Pharmaceuticals wins motion to dismiss False Claims Act Lawsuit
May 20,2020: Vanda Pharmaceuticals CEO’s proposal on clinical trial data sharing, covid-19 and Remdesivir
May 06,2020: Vanda Pharmaceuticals reports first quarter 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vanda Pharmaceuticals Inc – Key Facts
Vanda Pharmaceuticals Inc – Key Employees
Vanda Pharmaceuticals Inc – Key Employee Biographies
Vanda Pharmaceuticals Inc – Major Products and Services
Vanda Pharmaceuticals Inc – History
Vanda Pharmaceuticals Inc – Company Statement
Vanda Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vanda Pharmaceuticals Inc – Business Description
Product Category: Fanapt
Overview
Performance
Product Category: HETLIOZ
Overview
Performance
R&D Overview
Vanda Pharmaceuticals Inc – Corporate Strategy
Vanda Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Vanda Pharmaceuticals Inc – Strengths
Vanda Pharmaceuticals Inc – Weaknesses
Vanda Pharmaceuticals Inc – Opportunities
Vanda Pharmaceuticals Inc – Threats
Vanda Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vanda Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 28, 2020: Vanda Pharmaceuticals reports third quarter 2020 financial results
Aug 05, 2020: Vanda Pharmaceuticals reports second quarter 2020 financial results
May 20, 2020: Vanda Pharmaceuticals wins motion to dismiss False Claims Act Lawsuit
May 20, 2020: Vanda Pharmaceuticals CEO’s proposal on clinical trial data sharing, covid-19 and Remdesivir
May 06, 2020: Vanda Pharmaceuticals reports first quarter 2020 financial results
Apr 15, 2020: Vanda pharmaceuticals announces initiation of “calypso” to study the role of genetic variation in covid-19 infections in collaboration with University of Washington Medicine
Apr 08, 2020: Vanda Pharmaceuticals and The University of Illinois at Chicago announce partnership to identify novel antivirals against COVID-19
Feb 25, 2020: Vanda Pharmaceuticals reports fourth quarter and full year 2019 financial results
Feb 19, 2020: Vanda Pharmaceuticals appoints Stephen Ray Mitchell to Board of Directors
Jan 31, 2020: Vanda Pharmaceuticals comments on court ruling
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Vanda Pharmaceuticals Inc, Key Facts
Vanda Pharmaceuticals Inc, Key Employees
Vanda Pharmaceuticals Inc, Key Employee Biographies
Vanda Pharmaceuticals Inc, Major Products and Services
Vanda Pharmaceuticals Inc, History
Vanda Pharmaceuticals Inc, Subsidiaries
Vanda Pharmaceuticals Inc, Key Competitors
Vanda Pharmaceuticals Inc, Ratios based on current share price
Vanda Pharmaceuticals Inc, Annual Ratios
Vanda Pharmaceuticals Inc, Annual Ratios (Cont...1)
Vanda Pharmaceuticals Inc, Annual Ratios (Cont...2)
Vanda Pharmaceuticals Inc, Interim Ratios
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vanda Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Vanda Pharmaceuticals Inc (VNDA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Karur Vysya Bank Ltd:企業の戦略・SWOT・財務情報
    Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Organogenesis Inc:医療機器:M&Aディール及び事業提携情報
    Summary Organogenesis Inc (Organogenesis) is a regenerative medicine company that operates in the areas of bioactive wound healing and soft tissue regeneration. The company’s products include apligraf and dermagraft. Its dermagraft is used for the treatment of full-thickness diabetic foot ulcers. Or …
  • EDF Energy Holdings Ltd:電力:M&Aディール及び事業提携情報
    Summary EDF Energy Holdings Ltd (EDF Energy), a subsidiary of Electricite de France SA, is an energy utility and is one of the major producers of low carbon electricity in the UK. The company together with its subsidiaries carries out the generation, provision and supply of electricity and gas. It g …
  • Plexxikon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Plexxikon Inc (Plexxikon), a subsidiary of Daiichi Sankyo Company Ltd is a drug discovery company that concentrates on discovery and development of novel, small molecules. The company’s pipeline products include PLX3397 to treat adjuvant glioblastoma, neoadjuvant breast, melanoma and solid t …
  • Tetherex Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Tetherex Pharmaceuticals Corp (Tetherex Pharmaceuticals) is a clinical-stage biopharmaceutical company which develops novel medicines for the treatment of inflammation, thrombosis and tumor metastasis. Its lead pipeline product candidate SelK2, a humanized monoclonal antibody targets a cell …
  • Energy Transfer Equity, L.P.:企業のM&A・事業提携・投資動向
    Energy Transfer Equity, L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Energy Transfer Equity, L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventiona …
  • Keysight Technologies Inc:企業の戦略・SWOT・財務分析
    Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Taylor-DeJongh Inc:企業の戦略・SWOT・財務情報
    Taylor-DeJongh Inc - Strategy, SWOT and Corporate Finance Report Summary Taylor-DeJongh Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GenomicTree Inc:企業の製品パイプライン分析2018
    Summary GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung and …
  • Metalico Inc:企業の戦略的SWOT分析
    Metalico Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Thomson Reuters Corporation:企業の戦略・SWOT・財務情報
    Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report Summary Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BroadVision Inc (BVSN):企業の財務・戦略的SWOT分析
    Summary BroadVision Inc (BroadVision) operates as a digital technology service provider. It provides products such as vmoso. The company vmos product offers communication and collaboration, knowledge management, collaborative process management and enterprise integration. BroadVision also offers sec …
  • United Continental Holdings Inc:戦略・SWOT・企業財務分析
    United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Lekoil Ltd (LEK):企業の財務・戦略的SWOT分析
    Summary Lekoil Ltd (Lekoil) is an oil and gas exploration and production company with interests in Nigeria and Namibia. The company owns oil and gas exploration and production properties such as Otakikpo marginal field, Nigeria Dahomey Basin OPL310 and Nigeria Dahomey Basin OPL 325 in Nigeria, and B …
  • Kenya Power and Lighting Co Ltd (KPLA):企業の財務・戦略的SWOT分析
    Kenya Power and Lighting Co Ltd (KPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Voith GmbH & Co KGaA:企業の戦略的SWOT分析
    Voith GmbH & Co KGaA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Heineken NV:企業のM&A・事業提携・投資動向
    Heineken NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Heineken NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Crossject SA (ALCJ):企業の財務・戦略的SWOT分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company’s pipeline products include sumatriptan for the treatment of migraines and cluster headaches; adrenaline for the treatment of anaphylactic shock; hydrocortisone for the treatment of acute adrena …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆